
New approach to ovarian cancer treatment uses RNA-based nanodrugs
In a study conducted at Tel Aviv University (TAU), the protein CKAP5 (cytoskeleton-associated protein) was used for the first time as a therapeutic target for RNA-based nanodrugs. After identifying a genetically unstable mutation resistant to both chemotherapy and immunotherapy in the tissues of ovarian cancer, the researchers targeted these cells with lipid nanoparticles containing RNA… Read More